RU2015125307A - Комбинированная терапия - Google Patents
Комбинированная терапия Download PDFInfo
- Publication number
- RU2015125307A RU2015125307A RU2015125307A RU2015125307A RU2015125307A RU 2015125307 A RU2015125307 A RU 2015125307A RU 2015125307 A RU2015125307 A RU 2015125307A RU 2015125307 A RU2015125307 A RU 2015125307A RU 2015125307 A RU2015125307 A RU 2015125307A
- Authority
- RU
- Russia
- Prior art keywords
- inhibitor
- cdk4
- cyclin
- agent
- dependent kinase
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 4
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 4
- 229940124302 mTOR inhibitor Drugs 0.000 claims 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 4
- 229940126062 Compound A Drugs 0.000 claims 2
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 claims 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730661P | 2012-11-28 | 2012-11-28 | |
| US61/730,661 | 2012-11-28 | ||
| PCT/US2013/071659 WO2014085318A1 (en) | 2012-11-28 | 2013-11-25 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015125307A true RU2015125307A (ru) | 2017-01-10 |
Family
ID=49753505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015125307A RU2015125307A (ru) | 2012-11-28 | 2013-11-25 | Комбинированная терапия |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9408847B2 (enExample) |
| EP (1) | EP2925365A1 (enExample) |
| JP (2) | JP2016501221A (enExample) |
| KR (1) | KR20150089053A (enExample) |
| CN (1) | CN104812414A (enExample) |
| AU (4) | AU2013352406A1 (enExample) |
| BR (1) | BR112015012197A8 (enExample) |
| CA (1) | CA2891938A1 (enExample) |
| HK (1) | HK1211475A1 (enExample) |
| MX (1) | MX2015006809A (enExample) |
| RU (1) | RU2015125307A (enExample) |
| WO (1) | WO2014085318A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2764724C2 (ru) * | 2017-03-16 | 2022-01-19 | ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД. | Комбинированная терапия для лечения рака молочной железы |
| RU2769527C2 (ru) * | 2016-06-22 | 2022-04-01 | Эллипсес Фарма Лтд | Способы лечения ar+ рака молочной железы |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY161237A (en) * | 2011-07-01 | 2017-04-14 | Novartis Ag | Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer |
| US9527857B2 (en) | 2013-03-15 | 2016-12-27 | GI Therapeutics, Inc. | HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| DK3099717T3 (da) | 2014-01-31 | 2019-07-01 | Novartis Ag | Antistofmolekyler med tim-3 og anvendelser deraf |
| TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| EP4035664A3 (en) | 2014-03-28 | 2022-11-30 | Duke University | Treating cancer using selective estrogen receptor modulators |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| CA2979215A1 (en) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| CN106336412A (zh) * | 2015-07-10 | 2017-01-18 | 南开大学 | 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物 |
| CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
| EP3156406A1 (en) * | 2015-10-14 | 2017-04-19 | ratiopharm GmbH | Crystalline forms of ribociclib free base |
| SMT202200118T1 (it) | 2015-11-03 | 2022-05-12 | Janssen Biotech Inc | Anticorpi che legano specificamente pd-1 e loro usi |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| WO2018081211A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| CN110785187B (zh) | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN111214468B (zh) * | 2018-11-23 | 2021-02-05 | 苏州亚盛药业有限公司 | 新型药物组合物及其用途 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011240735B2 (en) * | 2010-04-13 | 2015-01-29 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer |
-
2013
- 2013-11-25 KR KR1020157016810A patent/KR20150089053A/ko not_active Ceased
- 2013-11-25 MX MX2015006809A patent/MX2015006809A/es unknown
- 2013-11-25 EP EP13802807.1A patent/EP2925365A1/en not_active Withdrawn
- 2013-11-25 CN CN201380061379.0A patent/CN104812414A/zh active Pending
- 2013-11-25 US US14/646,206 patent/US9408847B2/en not_active Expired - Fee Related
- 2013-11-25 HK HK15112282.5A patent/HK1211475A1/xx unknown
- 2013-11-25 WO PCT/US2013/071659 patent/WO2014085318A1/en not_active Ceased
- 2013-11-25 JP JP2015545145A patent/JP2016501221A/ja not_active Withdrawn
- 2013-11-25 RU RU2015125307A patent/RU2015125307A/ru not_active Application Discontinuation
- 2013-11-25 CA CA2891938A patent/CA2891938A1/en not_active Abandoned
- 2013-11-25 BR BR112015012197A patent/BR112015012197A8/pt not_active IP Right Cessation
- 2013-11-25 AU AU2013352406A patent/AU2013352406A1/en not_active Abandoned
-
2016
- 2016-11-25 AU AU2016262781A patent/AU2016262781A1/en not_active Abandoned
-
2018
- 2018-01-15 AU AU2018200323A patent/AU2018200323A1/en not_active Abandoned
- 2018-09-20 JP JP2018176231A patent/JP2019031500A/ja not_active Withdrawn
-
2019
- 2019-02-08 AU AU2019200881A patent/AU2019200881A1/en not_active Ceased
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2769527C2 (ru) * | 2016-06-22 | 2022-04-01 | Эллипсес Фарма Лтд | Способы лечения ar+ рака молочной железы |
| RU2764724C2 (ru) * | 2017-03-16 | 2022-01-19 | ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД. | Комбинированная терапия для лечения рака молочной железы |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150306104A1 (en) | 2015-10-29 |
| JP2019031500A (ja) | 2019-02-28 |
| KR20150089053A (ko) | 2015-08-04 |
| WO2014085318A1 (en) | 2014-06-05 |
| AU2018200323A1 (en) | 2018-02-01 |
| AU2016262781A1 (en) | 2016-12-15 |
| JP2016501221A (ja) | 2016-01-18 |
| CA2891938A1 (en) | 2014-06-05 |
| BR112015012197A2 (pt) | 2017-07-11 |
| US9408847B2 (en) | 2016-08-09 |
| MX2015006809A (es) | 2015-08-06 |
| EP2925365A1 (en) | 2015-10-07 |
| CN104812414A (zh) | 2015-07-29 |
| BR112015012197A8 (pt) | 2019-10-01 |
| AU2019200881A1 (en) | 2019-02-28 |
| AU2013352406A1 (en) | 2015-06-04 |
| HK1211475A1 (en) | 2016-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015125307A (ru) | Комбинированная терапия | |
| JP2016501221A5 (enExample) | ||
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| JP2016533366A5 (enExample) | ||
| EA201270373A1 (ru) | Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли | |
| EA202092671A1 (ru) | Оптимизированная комбинированная терапия и ее применение для лечения злокачественной опухоли и аутоиммунного заболевания | |
| EA201491399A1 (ru) | Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака | |
| EA201200260A1 (ru) | Гетероциклические гидразоны и их применение для лечения рака и воспаления | |
| MX373803B (es) | Terapia de combinación que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cáncer. | |
| GEP20237479B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| MX2015017201A (es) | Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga. | |
| EA200970932A1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа | |
| EA201390085A1 (ru) | Композиции ингибиторов киназ для лечения рака | |
| EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
| CY1116007T1 (el) | Ενωση ιμιδαζο[4,5-c]κινολιν-2-ονης και χρηση της ως διπλος αναστολεας της ρ13 κινασης/mtor | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| EA201590535A1 (ru) | Способы лечения локально прогрессирующего запущенного рака молочной железы | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| EA201270730A1 (ru) | ИНГИБИТОРЫ КИНАЗЫ Cdc7 И ИХ ПРИМЕНЕНИЕ | |
| MX387207B (es) | Inhibidores de proteína quinasa, método de preparación y su uso médico. | |
| EA201491623A1 (ru) | Замещенные пирролидин-2-карбоксамиды | |
| PH12016502355B1 (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20200325 |